INTERVIEW: Genexine Aiming To Become Global Player
This article was originally published in PharmAsia News
Genexine is set to progress and expand this year the clinical development of its leading assets, orphan disease drugs and cancer immunotherapies. The South Korean biotech company's CEO talks in an interview with PharmAsia News about its R&D and business strategies, as well as the challenges faced by the wider Korean biotech industry.
Register for our free email digests: